Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents.
Guillermo Garcia-ManeroRayna K MatsunoAli McBrideHina MohammedDanny IdryoRonda BroomeAutumn HerrimanTiffany JohnsonKristiana WilkinsonAndrew SchragColden JohansonMonika IzanoAdeola MakindeSudipto MukherjeePublished in: Clinical lymphoma, myeloma & leukemia (2024)
Our results indicate that primary ESA failure is largely unrecognized and that many patients should be considered for alternative treatments.